Floatz logo

A-DMDT390-BISFV(UCHT1)

Mycosis Fungoides

Virogen Biotechnology Inc.protein_peptidePhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
81/ 100

Competitive context

50 Active assets in the Mycosis Fungoides cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Virogen Biotechnology Inc.
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
Mayo Clinic
Phase 4BBB
METHOTREXATE
Polish Lymphoma Research Group
Phase 4BBB

View all 50 →

Same molecule, other indications

A-DMDT390-BISFV(UCHT1) is also rated in:

T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
T-cell leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
Sezary syndromeDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →